Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:WVE News 16 December 2025 - 3 February 2026

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
3 February 2026
······
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

New York, January 10, 2026, 21:25 EST — Market closed Shares of Wave Life Sciences Ltd dropped 6.7% on Friday, ending the day at $13.84. The stock swung between a high of $15.09 and a low of $13.76 during the session. As the J.P. Morgan Healthcare Conference week kicks off, investors are eyeing Wave’s stock for any new insights on its pipeline and upcoming milestones. CEO Paul Bolno is set to speak on Tuesday. (GlobeNewswire) The San Francisco event is a key date for healthcare investors and bankers, sparking deal chatter and fresh moves in biotech. This week, a Reuters
11 January 2026
·····
Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

New York, January 9, 2026, 13:20 (EST) — Regular session Wave Life Sciences Ltd shares fell about 5.6% on Friday, down 83 cents at $14.00, after trading between $13.99 and $15.09. The drop came even as biotech exchange-traded funds rose, with the SPDR S&P Biotech ETF up about 1% and the iShares Nasdaq Biotechnology ETF up about 0.5%. The move matters because Wave has become a high-beta obesity trade in the biotech tape, and the stock has been swinging on every new data point and funding headline. Traders have been leaning on near-term catalysts rather than fundamentals, and those catalysts
9 January 2026
·····
Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

New York, Jan 7, 2026, 12:57 (EST) — Regular session Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE. The spark this week came from Arrowhead Pharmaceuticals, which on Tuesday posted interim results from its obesity candidates aimed at INHBE or its receptor, ALK7. Arrowhead said its ARO-INHBE nearly doubled weight loss when paired with Eli Lilly’s tirzepatide, and drove what an outside expert called “dramatic and rapid reductions in visceral fat,” the fat that builds
7 January 2026
·····
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up

New York, January 6, 2026, 11:28 EST — Regular session Wave Life Sciences Ltd shares (WVE.O) jumped about 17% on Tuesday, extending sharp swings in the obesity drug trade as investors sized up the next set of clinical readouts. The stock was up 17.2% at $17.58 in morning trade on Nasdaq, after moving between $14.15 and $19.49, with about 7.0 million shares traded. The move shows how quickly sentiment can shift in obesity-linked biotechs, where small early-stage updates often drive outsized price action. Investors are hunting for approaches that can cut harmful fat while preserving muscle, a sticking point for
6 January 2026
···
Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

New York, January 5, 2026, 1:09 PM ET — Regular session Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged an investor-conference appearance next week. The move matters because the J.P. Morgan Healthcare Conference often sets the tone for biotech investing early in the year, and Wave’s stock has become closely tethered to expectations for updates on its obesity program and financing needs. Biotech lagged more broadly, with the SPDR S&P Biotech ETF down about 2.1% and the iShares Nasdaq
5 January 2026
····
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

New York, Jan 4, 2026, 12:46 ET — Market closed Wave Life Sciences shares closed down 6.2% on Friday at $15.95, with the Nasdaq-listed biotech swinging between $15.53 and $17.23 in the session. The drop matters because Wave’s stock has become a high-beta proxy for investor appetite for next-generation obesity treatments, where early clinical signals can move valuations sharply. The next company update investors care about is already on the calendar: Wave has guided to additional INLIGHT trial data in the first quarter. SEC Wave is developing RNA medicines, including WVE-007, a small interfering RNA (siRNA) therapy that aims to
4 January 2026
·····
Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

Wave Life Sciences stock drops 6% as WVE traders size up next obesity data

NEW YORK, Jan 3, 2026, 20:55 ET — Market closed Wave Life Sciences Ltd (WVE) shares closed down 6.2% on Friday at $15.95, ending the first full U.S. trading session of 2026 with a sharp pullback. The slide matters because Wave has become an event-driven obesity trade after a December clinical update on its experimental fat-loss drug drew heavy attention from biotech investors. With U.S. markets closed for the weekend, traders are now looking past Friday’s drop to the next scheduled clinical follow-ups and to how Wave’s recent fundraising affects the stock’s risk-reward into 2026. Nasdaq trading data showed WVE
4 January 2026
····
Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout

NEW YORK, January 2, 2026, 14:13 ET — Regular session Wave Life Sciences Ltd shares slid on Friday, giving back part of last month’s obesity-driven run as the biotech sector wobbled in the first U.S. session of 2026. The stock was down about 8.5% at $15.55 as of 2:13 p.m. ET. The retreat matters because Wave has become a high-volatility obesity “story stock,” with investors trying to price the upside of an early-stage program against the risks that come with thin clinical data and heavy funding needs. The shares more than doubled on December 8 after the company posted interim
2 January 2026
·····
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is down about 1.07% and iShares Nasdaq Biotechnology ETF (IBB) is down about 0.63%—even as the broader market edges higher, with SPY and QQQ both modestly in the green. That “WVE down while the market is up” headline can look ominous—until you zoom out and remember what happened earlier this month: Wave’s stock ripped higher on early obesity data, then the
26 December 2025
·····
Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday trading, WVE stock fell roughly mid-single digits, hovering in the mid-$15 range after closing around $16.34 the prior session, according to market data and widely circulated market recaps. StockAnalysis+1 That pullback matters because it comes right after a dramatic early-December surge tied to Wave’s obesity program—and immediately following a large equity financing that materially changes the company’s cash position and
18 December 2025
····
Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

Wave Life Sciences (WVE) Stock News Today: Oppenheimer Lifts Target to $32 as WVE-007 Obesity Data Fuels Volatility

December 16, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight after a roller-coaster week that mashed together three classic biotech ingredients: eye-popping early clinical data, a rapidly upsized stock offering, and a stack of Wall Street price-target hikes. As of 14:38 UTC on Tuesday (Dec. 16, 2025), Wave Life Sciences stock was trading at $16.94, up about 5.2% on the day, with an intraday range of $16.14 to $17.27, according to market data. What changed today: Oppenheimer raised its price target to $32 from $24 and reiterated an Outperform rating, pointing to what it called
16 December 2025
····
1 2

Stock Market Today

Blockchain’s New Pitch: Tracking Supply-Chain Emissions for a Price

Blockchain’s New Pitch: Tracking Supply-Chain Emissions for a Price

7 February 2026
Blockchain industry groups are promoting supply-chain emissions tracking and data transparency, not crypto trading, as key business uses. Companies face mounting pressure to map Scope 3 emissions, which are often hard to verify. Past blockchain supply-chain projects, including Maersk’s TradeLens, struggled with adoption when partners failed to participate.
Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Go toTop